HEAR. HELP. HEAL. HOPE.
The ADAP Advocacy Association
mission is to promote and enhance the AIDS Drug Assistance Programs (ADAPs)
and improve access to care for persons living with HIV/AIDS.
works with advocates, community, health care, government, patients,
pharmaceutical companies and other stakeholders to assure that access to
services recognize and afford persons living with HIV/AIDS to enjoy a healthy
is the only national grassroots organization focused exclusively on ADAPs
and ensuring that there are adequate resources nationwide to eliminate or
prevent waiting lists for services. Our purpose is to better engage people
living with HIV/AIDS by providing a platform whereby they can offer their
personal experiences, challenges, knowledge, insight and solutions to solving
this perpetual problem.
ADAP Advocacy Association Issues Call for Nominations for
its 2015 Annual ADAP Leadership Awards
Awards to recognize leaders who are working to improve access to care
WASHINGTON, D.C. (March 5, 2015) - The ADAP Advocacy Association, also known
today opened nominations for its 2015 Annual ADAP Leadership Awards. The
awards recognize individual, community, government and corporate leaders
who are working to improve access to care and treatment under the AIDS Drug
to submit nomination.
Need for National Data on HCV Prevention, Care, and Treatment
the National HCV Epidemic
By: Marissa Tonelli, Senior Manager, HealthHCV Initiative
The Centers for Disease Control and Prevention (CDC) estimates 3.2 million
people in the United States are living with chronic hepatitis C infection;
80% of whom will develop chronic liver disease, close to a quarter of whom
will go on to develop cirrhosis; and, about 5% of whom will die as a result
of chronic HCV infection. These continue to be estimates as a result of limited
national data and the disparate nature of the datasets, which have been barriers
to fully understanding the extent and details of the national HCV epidemic.
Without a fully resourced, national hepatitis surveillance system, clinical
providers and public health officials rely on limited data to inform
According to the European Association for the Study of Liver Disease (EASL)
Recommendations on Treatment of Hep C, inaccurate data, as well as lack of
data for specific sub-populations, is an element hindering the design of
effective public health interventions and limits the development of provider
guidelines. Collection and analysis of national data related to HCV prevention,
care, and treatment is essential to informing effective public health and
clinical interventions to impact the epidemic.
CLICK HERE to read more.
ADAPs with Waiting Lists
(35 individuals in 1 state(s) on the ADAP Waiting List as of
July 28, 2014)
Source: The ADAP Watch, National Alliance of State
& Territorial AIDS Directors (NASTAD).
Eleven ADAPs have had cost-containment measures in place since April 1, 2013
(reported as of July 15, 2014).
No ADAPs currently anticipate additional cost-containment measures prior
to March 31, 2015.
to the ADAP Watch